Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes.

Ahrén, Bo

Published in:
Vascular Health and Risk Management

DOI:
10.2147/VHRM.S33934

2013

Citation for published version (APA):
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

Bo Ahrén
Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University, Lund, Sweden

Abstract: Type 2 diabetes carries a risk for hypoglycemia, particularly in patients on an intensive glucose control plan as a glucose-lowering strategy, where hypoglycemia may be a limitation for the therapy and also a factor underlying clinical inertia. Glucose-lowering medications that increase circulating insulin in a glucose-independent manner, such as insulin and sulfonylurea therapy, are the most common cause of hypoglycemia. However, other factors such as a delayed or missed meal, physical exercise, or drug or alcohol consumption may also contribute. Specific risk factors for development of hypoglycemia are old age, long duration of diabetes, some concomitant medication, renal dysfunction, hypoglycemia unawareness, and cognitive dysfunction. Hypoglycemia is associated with acute short-term symptoms related to either counterregulation, such as tachycardia and sweating, or to neuroglycopenia, such as irritability, confusion, and in severe cases stupor, coma, and even death. However, there are also long-term consequences of hypoglycemia such as reduced working capacity, weight gain, loss of self-confidence with reduced quality of life, and increased risk for cardiovascular diseases. For both the patients, the health care system, and the society at large, hypoglycemia carries a high cost. Strategies to mitigate the risk of hypoglycemia include awareness of the condition; education of patients, relatives, and health care providers; and selecting appropriate glucose-lowering medication that also judges the risk for hypoglycemia to prevent this complication. This article summarizes the current knowledge of hypoglycemia and its consequences with a special emphasis on its consequences for the choice of glucose-lowering therapy.

Keywords: type 2 diabetes, hypoglycemia, treatment, sulfonylurea, incretin therapy, insulin

Hypoglycemia as a factor behind clinical inertia

Intensive glucose control is an important glucose-lowering strategy in the treatment of type 2 diabetes to reduce the risk for diabetic complications. Intense glucose lowering is achieved in many patients by a combination of medications, including sulfonylureas and insulin. Although careful titration of insulin therapy and intensive therapy with some sulfonylureas can achieve a good glycemic control without significant risk for hypoglycemia, a common limitation of intensive glucose lowering therapy is an increased risk for hypoglycemia. Consequently, today type 2 diabetes is associated with a substantial incidence rate of hypoglycemia. Hypoglycemia has a negative impact for the well-being of the patients, both in the short-term and the long-term. In addition, hypoglycemia also carries a high cost, not only for the individual patient, but also for the health care system and society at large.

The risk for hypoglycemia is also an important factor underlying clinical inertia, which is a key consequence of inadequate glycemic control in patients with...
type 2 diabetes. Clinical inertia is the failure to advance therapy in patients who are not sufficiently controlled in relation to a glycemic target. This may be related both to a failure to initiate therapy when needed and to the failure of patients to adhere to the prescribed therapy. Several factors may underlie clinical inertia, related to the knowledge and attitude of health care providers, organizational factors, and the patients. Fear of hypoglycemia is, however, a common denominator for both health care providers and patients in regard to clinical inertia. Fear of hypoglycemia may prevent health care providers from suggesting intensification of glucose-lowering therapy and may also diminish the desire of patients to adhere to prescribed medication. Therefore, hypoglycemia not only carries the risk of acute symptoms and long-term risk, but may also prevent the use of adequate therapy for glucose control.

**Definition of hypoglycemia**

There is no generally accepted criterion for hypoglycemia, which makes it difficult to compare studies in regard to frequency of the condition. The American Diabetes Association (ADA) defines hypoglycemia as plasma glucose at 3.9 mmol/L or lower, whereas the European Agency for Evaluation of Medicinal Products used 3.0 mmol/L as the cutoff value for hypoglycemia. For most patients, symptoms of hypoglycemia occur in the range of 3.4–3.6 mmol/L and in many clinical trials, a cutoff level of 3.1 mmol/L is commonly used. It was recently suggested that 3.5 mmol/L would be a reasonable definition of hypoglycemia, because at this level, a clear glucose counterregulation has usually been stimulated. There is also a clinical definition of hypoglycemia, in that grade 1 hypoglycemia (mild hypoglycemia) is defined as a hypoglycemic event that is self-treated by the patient, whereas a grade 2 (severe) hypoglycemia requires the assistance of another person to administer therapy (for example glucose or glucagon).

It should be emphasized that many events of hypoglycemia observed by patients are not associated with glucose measurements and therefore are defined by the patients according to symptoms rather than a glucose cutoff level. The ADA Workgroup on Hypoglycemia has therefore divided hypoglycemia into five different categories: (1) severe hypoglycemia (an event requiring the assistance of another person regardless of glucose levels), (2) documented symptomatic hypoglycemia (typical symptoms and a confirmed glucose level ≤ 3.9 mmol/L), (3) asymptomatic hypoglycemia (glucose level ≤ 3.9 mmol/L but without typical symptoms), (4) probable symptomatic hypoglycemia (typical symptoms but without confirmation of glucose determination), and (5) relative hypoglycemia (typical symptoms but with a glucose level > 3.9 mmol/L). These different forms of hypoglycemia are of importance from a clinical point of view, since the consequences for choice of and adherence to glucose-lowering therapy in praxis is governed by the patient’s symptoms rather than a predefined hypoglycemia cutoff level.

**Symptoms and consequences of hypoglycemia**

**Acute symptoms**

The most obvious consequences of hypoglycemia are the acute symptoms, such as tachycardia, shakiness, anxiety, irritability, and hunger, which have a negative impact on the patient’s well-being, social activities, and working abilities (Table 1). These symptoms are mainly caused by sympathoadrenal activation, which is a part of the glucose counterregulatory response and initiated at glucose levels ≈ 3.5 mmol/L. More severe hypoglycemia also creates neuroglycopenia, which occurs when glucose levels are below the threshold for sufficient cerebral supply (usually ≤ 3.0 mmol/L). Neuroglycopenia results in a characteristic series of symptoms, such as difficulty to concentrate, weakness and dizziness, headache, confusion, blurred vision and slurred speech, seizure, loss of consciousness, and coma. Severe hypoglycemia may also be associated with increased mortality. For example, it has been shown that severe hypoglycemia due to sulfonylurea carries a 9% mortality rate.

**Reduced quality of life**

An important consequence of hypoglycemia, particularly repeated hypoglycemia, is reduced quality of life, as has been demonstrated. Reduced quality of life in patients who have experienced hypoglycemia may have several causes and signs. A common denominator is fear of a new hypoglycemic episode. In a questionnaire study, approximately 25% of patients with type 2 diabetes who had experienced mild hypoglycemia (2.9–4.0 mmol/L) and more than 80% of patients with severe hypoglycemia (<2.9 mmol/L) responded “sometimes” or “always” to the question whether they had a fear of recurrent hypoglycemic episodes. Furthermore, a survey on fear of hypoglycemia showed that patients who had experienced hypoglycemia had a markedly higher fear for a new hypoglycemic event and this increased fear was related to the severity and frequency of hypoglycemia. This increased fear of a new hypoglycemic episode may in turn result in the deterioration of glycemic control due to a
Risk factors for cardiovascular diseases after hypoglycemia in a study population of more than 44,000 patients with type 2 diabetes compared to a control group. Age of patients, duration of diabetes, and HbA1c did not differ between the groups.

The increased risk for cardiovascular diseases due to hypoglycemia might have several causes. One causal factor may be the weight gain associated with defensive eating, since increased body weight is associated with cardiovascular diseases. Other factors resulting in increased cardiovascular risk after hypoglycemia may be due to catecholamines released locally in the heart during hypoglycemic episodes. This may result in increased heart rate, silent myocardial ischemia, prolonged QT time, and angina and myocardial infarction. There is also increased thrombotic tendency with decreased thrombolysis, endothelial dysfunction with reduced vasodilatation, and inflammation due to cytokine release in association with hypoglycemia.

Hypoglycemia is also associated with other negative long-term consequences. One such consequence is the development of cognitive dysfunction and dementia. Hence, hypoglycemia not only carries short-term risks, but may also be associated with increased long-term risk for various complications.

Incidence of hypoglycemia
Several factors make it difficult to establish the incidence rate of hypoglycemia in type 2 diabetes. One factor is that the incidence of hypoglycemia in type 2 diabetes is related to the aggressiveness of the therapy, as recently demonstrated in a meta-analysis of large clinical trials.
showing that intensive glucose-lowering therapy increased the risk for hypoglycemia by more than 100%. Another factor is that reports of hypoglycemia may depend on cut-off levels for glucose, which may be different in different studies, or by patients reporting symptomatic non-confirmed hypoglycemia, the definition of which is dependent on patient choice and therefore is different between patients. A third factor is that many events of hypoglycemia go undetected. Thus, one study using continuous glucose monitoring to estimate hypoglycemic episodes reported that approximately 50% of patients had unrecognized hypoglycemic events. This hypoglycemia unawareness is a clinical reality defined by the failure of the patient to recognize a hypoglycemic episode. Furthermore, patients may also refrain from reporting hypoglycemic episodes, since the hypoglycemic events are either forgotten, taken naturally, or simply not reported, the latter of which may be due to the fear that reporting hypoglycemic episodes might have a negative impact on, for example, employment or the ability to keep a driving license. It has been reported that only approximately 15% of hypoglycemic episodes in patients with type 2 diabetes were reported to the doctor.

Some data, however, exist in regard to the hypoglycemia incidence rate in clinical practice. The UK Hypoglycemia Study Group reported that 39% of patients treated with sulfonylurea, 51% of patients treated with insulin for less than 2 years, and 64% of patients treated with insulin for more than 5 years experienced hypoglycemia during a study period of 8–10 months. Furthermore, 7% of patients treated with sulfonylurea or insulin for less than 2 years and 25% of patients treated with insulin for more than 5 years had experienced severe hypoglycemia. Moreover, a population-based study exploring hypoglycemia over a 1-month period revealed an annual rate of hypoglycemia in insulin-treated patients with type 2 diabetes of 0.35 events per patient. In addition, one study demonstrated that 25% of patients treated with insulin had at least one episode of severe hypoglycemia every year. An epidemiological study reported that hypoglycemia occurred in 16% of patients with type 2 diabetes treated with sulfonylureas over a mean period of 7 months. One study reported that severe hypoglycemia occurred annually in 0.8% of patients treated with sulfonylurea and 7% of patients treated with insulin. More studies are required, however, for establishing the incidence of hypoglycemia in different patient populations, and these studies need uniform protocols regarding reporting and definitions.

**Risk factors for hypoglycemia**

Table 1 summarizes the most common causes and risk factors for hypoglycemia in patients with type 2 diabetes. The most common cause is the use of glucose-lowering medication, which increases circulating insulin in a glucose-independent manner. Sulfonylureas and insulin are of particular importance in this context. However, other factors apart from medication contribute to increased risk for hypoglycemia. One such factor is delayed or missed meal intake or ingestion of a smaller meal than planned. It has actually been shown that subjects with regular eating habits have a lower risk for hypoglycemia than patients who have irregular eating habits. Furthermore, people undertaking fasting, such as during Ramadan, have an increased risk of hypoglycemia during these periods. Increased physical exercise also carries an increased risk of hypoglycemia due to increased insulin sensitivity. Moreover, drug or alcohol consumption may cause hypoglycemia, particularly in conjunction with glucose-lowering agents, since it delays glucose counterregulation. These causes of hypoglycemia may be of particular importance in certain patient groups, which therefore have an increased risk for hypoglycemia. One such risk factor for hypoglycemia is old age. Increased risk for hypoglycemia in elderly subjects may be due to increased sensitivity to medication and compromised counterregulation. Also, long duration of diabetes, renal dysfunction, peripheral neuropathy, obesity, hypoglycemia unawareness, and cognitive dysfunction increase the risk for hypoglycemia. In addition, some medications, such as angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, may mask the symptoms of hypoglycemia, thereby aggravating a hypoglycemic event, and some medication will increase circulating concentrations of sulfonylurea which increases the risk for hypoglycemia in patients treated with sulfonylureas. These agents include those which inhibit renal excretion of sulfonylurea (aspirin and allopurinol), displace sulfonylureas from albumin (aspirin, warfarin, sulphonamide, trimethoprim, and fibrates), or reduce metabolism of sulfonylurea (warfarin and mono-amine oxidase inhibitors), as reviewed by Amiel et al.

**Cost of hypoglycemia**

Hypoglycemia is associated with a high cost for the patient, the health care system, and society at large. Table 1 lists some of the cost-driving factors induced by hypoglycemia. For example, 25% of hospital admissions in elderly patients are due to severe hypoglycemia and 95% of emergency visits due to drug adverse events within endocrinology are due to hypoglycemia, and these emergency visits carry a high cost.
Other costs related to hypoglycemia are an increased burden on the health care system, including telephone consultations, hospitalization costs, and increased use of strips for the self-monitoring of blood glucose, as well as use of glucose or glucagon administration. Hypoglycemia may also result in absence from work and reduced productivity and accidents. Attempts to estimate the total cost of hypoglycemia for the health care system have arrived at very high cost. To this estimated cost will be added the reduced quality of life, reduced or even lost work capacity, and increased long-term complications. Thus, it is clear that hypoglycemia carries a financial burden at several levels of society and therefore that strategies to mitigate the risk for hypoglycemia will be cost-saving strategies.

**Implications for prevention and therapy of hypoglycemia**

The high frequency of hypoglycemia in type 2 diabetes and its important consequences, including the high cost, imply that it is of importance to develop strategies to mitigate the risk of hypoglycemia. Such strategies should involve increasing the awareness of hypoglycemia and its mechanisms and symptoms among patients, relatives, health care providers, and society at large. Such awareness should also include knowledge of causes and risk factors for hypoglycemia. A second strategy should be educating the patients, relatives, and health care providers about hypoglycemia. This includes teaching about symptoms, risk factors, and self-glucose-monitoring so that food or glucose ingestion may be initiated when glucose levels are low. It is also important to increase knowledge among patients, relatives, and the surrounding society about how to handle glucagon for injection in cases of severe hypoglycemia. An interesting educational program was recently reported from the UK. A third strategy to prevent and avoid hypoglycemia is to make the focus of glucose-lowering therapy include lowering the risk of hypoglycemia in addition to improving glycemic control.

Therapies which carry a low risk of hypoglycemia might do so due to a glucose-dependent mechanism to increase circulating insulin levels in combination with effects to prevent and protect from hypoglycemia by supporting physiological glucose counterregulation, which is triggered by reducing glucose to the range of 3.6–4.0 mmol/L. This counterregulation involves several counter-regulatory hormones. Figure 1 illustrates the most important glucose counterregulatory mechanisms: inhibition of insulin secretion from β-cells (occurs at <4 mmol/L); stimulation of glucagon, adrenaline, and cortisol secretion; and activation of the sympathetic nerves (occurs usually at glucose levels = <3.6–3.9 mmol/L), which increase liver glucose output. Rapid glucagon counterregulation is of marked importance to defend and combat acute hypoglycemia, and this is dependent on reduced intra-islet insulin levels, a direct action of low glucose on α-cells, activation of the autonomic nerves, and stimulation by adrenaline released from the adrenals (Figure 2).

**Glucose-lowering medication and hypoglycemia**

**Metformin**

First-line pharmacological glucose-lowering therapy in most guidelines is metformin. It has been used for more than 50 years and, although its detailed mechanism of action is still not established, it increases insulin sensitivity and reduces hepatic glucose production. When used as monotherapy, it carries a low risk of hypoglycemia. In the UKPDS, which was a long-term study, the risk for mild hypoglycemia in patients treated with metformin as monotherapy was only 0.3% per year. Similarly, several clinical trials have shown that the risk for mild hypoglycemia in patients on metformin alone is very low, with no risk for severe hypoglycemia.

**Figure 1** Symptoms and defence mechanisms in relation to glucose levels in the subnormal range.
Table 2 Incidence rates of grade 1 hypoglycemia in placebo-controlled 26–30 week clinical trials in which incretin therapy or placebo has been added to ongoing metformin

<table>
<thead>
<tr>
<th>Study group</th>
<th>Hypoglycemia</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exenatide + metformin</td>
<td>5.3%</td>
<td>71</td>
</tr>
<tr>
<td>Metformin + placebo</td>
<td>5.3%</td>
<td></td>
</tr>
<tr>
<td>Liraglutide + metformin</td>
<td>3.0%</td>
<td>72</td>
</tr>
<tr>
<td>Metformin + placebo</td>
<td>3.0%</td>
<td></td>
</tr>
<tr>
<td>Sitagliptin + metformin</td>
<td>1.3%</td>
<td>73</td>
</tr>
<tr>
<td>Metformin + placebo</td>
<td>2.1%</td>
<td></td>
</tr>
<tr>
<td>Saxagliptin + metformin</td>
<td>0.5%</td>
<td>74</td>
</tr>
<tr>
<td>Metformin + placebo</td>
<td>0.6%</td>
<td></td>
</tr>
<tr>
<td>Vildagliptin + metformin</td>
<td>0.5%</td>
<td>75</td>
</tr>
<tr>
<td>Metformin + placebo</td>
<td>0.5%</td>
<td></td>
</tr>
<tr>
<td>Alogliptin + metformin</td>
<td>0.0%</td>
<td>76</td>
</tr>
<tr>
<td>Metformin + placebo</td>
<td>1.0%</td>
<td></td>
</tr>
<tr>
<td>Linagliptin + metformin</td>
<td>0.6%</td>
<td>77</td>
</tr>
<tr>
<td>Metformin + placebo</td>
<td>2.8%</td>
<td></td>
</tr>
</tbody>
</table>

Notes: In none of the reported studies, was there a single case of grade 2 hypoglycemia. Percentage refers to the percentage of patients with at least one hypoglycemic episode during the study period.

Table 2 shows the frequency of hypoglycemia in 6-month trials on patients treated with metformin. Since metformin increases insulin sensitivity, it may carry an increased risk when combined with agents increasing insulin levels, such as sulfonylurea or exogenous insulin.

Sulfonylurea

When metformin is insufficient to reduce glycemia when given in monotherapy, sulfonylureas may be added. Sulfonylureas have been used for more than 50 years and they potently stimulate insulin secretion through a glucose-independent mechanism on pancreatic β-cells, thereby increasing circulating insulin levels.49 This results in a good glucose-lowering ability, but hypoglycemia is a common adverse event.7,19,35 It should be emphasized that there is a difference in the risk of hypoglycemia with different sulfonylureas, with the newer forms (gliclazide, glimepiride, and glipizide) having a lower risk than the first and second generations of sulfonylureas (tolbutamide and glibenclamide).4,50,51 This higher risk for hypoglycemia with the older generations of sulfonylureas might be explained by their action to stimulate β-cell function over a long period of time and at low glucose in combination with compromised glucagon counterregulation during hypoglycemia. Therefore, sulfonylureas may inhibit glucose counterregulation, as has been demonstrated for the older generation sulfonylureas, tolbutamide52 and glibenclamide.53

Thiazolidinediones

Thiazolidinediones have been used as a second- or third-line therapy since the end of the 1990s. They act by sensitizing muscle, adipose tissue, and the liver to insulin and have been shown to efficiently reduce glycemia.48 Thiazolidinediones carry a similar risk for hypoglycemia as metformin and lower than sulfonylureas. This was clearly demonstrated in the ADOPT (diabetes outcome progression trial) study, in which monotherapy with rosiglitazone, metformin, and glibenclamide was examined over a 4-year study period: hypoglycemia occurred in approximately 10% of patients on rosiglitazone versus 12% of patients on metformin and more than 38% of patients on glibenclamide.54

Alpha glucosidase inhibitors

Alpha glucosidase inhibitors reduce glucose by inhibiting glucose uptake into the circulation after meal ingestion due to inhibition of the intestinal brush border enzyme α-glucosidase, which results in delayed hydrolysis of ingested polysaccharides and oligosaccharides.55 They are used either as monotherapy or as an add-on to metformin and reduce glucose. Since these inhibitors do not increase insulin levels, the risk for hypoglycemia is low.55

Incretins

Another option to add to metformin is incretin therapy, which is based on the glucose-lowering action of the gut incretin hormone glucagon-like peptide-1 (GLP-1) and used either as injectable agonists of the GLP-1 receptor or oral tablets which inhibit dipeptidyl peptidase-4 (DPP-4), the enzyme which inactivates GLP-1.56 Both GLP-1 receptor agonists and DPP-4 inhibitors have a low risk for hypoglycemia (Table 2).58 This is due to a combination of a glucose-dependent stimulation of insulin secretion by GLP-159 and a preserved glucagon counterregulation to hypoglycemia as shown both for the GLP-1 receptor agonist exenatide60 and the DPP-4 inhibitor vildagliptin.61 Incretin therapy is also associated with a low risk of hypoglycemia when added to insulin therapy as has been demonstrated in several studies both for GLP-1 receptor agonists62,64 and DPP-4 inhibitors.65-67

Insulin

Careful titration of insulin therapy can achieve a good glycemic control without significant risk for hypoglycemia.2,3 However, in clinical practice, insulin treatment is usually associated with a high risk of hypoglycemia in type 2 diabetes2,31,68 and may even result in omission or non-adherence to the therapy.69 It should be emphasized that more modern insulin types are associated with a lower risk of hypoglycemia than older insulins. Thus, it has been shown that long-acting insulin analogues have a lower risk for hypoglycemia than medium-acting neutral protamine Hagedorn (NPH) insulin.70
Conclusion
Hypoglycemia is common not only in type 1 diabetes, but also in type 2 diabetes. It has negative consequences for both the daily life and well-being of the patient, for the glycemic control of diabetes, and for long-term risk of complications. Hypoglycemia is also associated with a high cost for the patient, the health care system, and society at large. The mitigation of the risk of hypoglycemia should include a strategy of increasing awareness of the risk; education of patients, relatives, and health care providers; and a careful choice of glucose-lowering medication taking into consideration the risk for hypoglycemia when selecting the therapy for the individual patient.

Disclosure
The author has received honoraria for lecturing and membership in advisory boards for Bristol Myers Squibb, GlaxoSmithKline, Lilly, Novartis, Novo Nordisk, Merck, AstraZeneca, and Sanofi-Aventis, all of which are companies producing GLP-1 receptor agonists or DPP-4 inhibitors. The author reports no other conflicts of interest in this work.

References
Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide sup
51. Stahl M, Berger W. Higher incidence of severe hypoglycemia
49. Rendell M. The role of sulphonylureas in the management of type 2
47. Frier BM. How hypoglycemia can affect the life of a person with
45. Greco D, Angileri G. Drug-induced severe hypoglycemia in type 2
43. Quilliam BJ, Simeone JC, Ozbay AB, Koqut SJ. The incidence and costs
41. Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients
39. Greco D, Angileri G. Drug-induced severe hypoglycemia in type 2
38. Schejter YD, Turvall E, Ackerman Z. Characteristic of patients with
36. Holstein A, Hammer C, Hahn M, Kilamadayil NS, Kovacs P. Severe
Ahrén patients with type 2 diabetes.
presses glucagon secretion during insulin-induced hypoglycemia in
leading to hospital admission in type 2 diabetic patients treated
51. Stahl M, Berger W. Higher incidence of severe hypoglycemia
leading to hospital admission in type 2 diabetic patients treated
52. Peacey SR, Rostami-Hodjegan A, George E, Tucker GT, Helkler SR.
The use of tolbutamide-induced hypoglycemia to examine the intrasplit
role of insulin in mediating glucagon release in normal humans. J Clin
Endocrinol Metab. 1997;82(5):1458–1461.
53. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide sup
presses glucagon secretion during insulin-induced hypoglycemia in
patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84(9):
3140–3145.
55. Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus: a critical
56. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2
1239–1245.
59. Ahrén B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on
islet function and insulin sensitivity in noninsulin-dependent diabetes
60. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide
(synthetic exendin-4) on glucose-dependent insulin secretion and counter
responsiveness to both hyper- and hypoglycemia in patients with type 2
Group. Sequential intensification of metformin treatment in type 2 dia
betes with liraglutide followed by randomized addition of basal insulin
agonist albiglutide vs titrated prandial lispro added on to titrated basal
insulin in type 2 diabetes (T2D) uncontrolled on glargine plus oral
agents: similar glycemic control weight loss and less hypoglycemia.
lixisenatide in type 2 diabetes insufficiently controlled with basal insulin ±
65. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S.
Addition of vildagliptin to insulin improves glycemic control in type 2
of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
67. Taborsky GJ Jr, Mundinger TO. Minireview: The role of the autonomic
nervous system in mediating the glucagon response to hypoglycemia.
68. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on
suppression of hepatic glucose production and stimulation of glucose
uptake in type 2 diabetes: a systematic review. Diabetologia. 2006;
49(3):434–441.
69. Rendell M. The role of sulphonylureas in the management of type 2
70. Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today:
matter of selectivity of sulphonylureas. Diabetes Obes Metab. 2012;14
71. Stahl M, Berger W. Higher incidence of severe hypoglycemia
leading to hospital admission in type 2 diabetic patients treated
72. Seino S, Takahashi H, Takahashi T, Shibasaki T. Treating diabetes today:
matter of selectivity of sulphonylureas. Diabetes Obes Metab. 2012;14
73. Charbonnel B, Karasik A, Liu J, Wu M, Meiningier G; Sitagliptin Study
Group. Saxagliptin as add-on therapy in patients with poorly controlled type 2
diabetes on insulin alone or insulin combined with metformin. Curr Med
74. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency
lixisenatide in type 2 diabetes insufficiently controlled with basal insulin ±
76. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S.
Addition of vildagliptin to insulin improves glycemic control in type 2
of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
78. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency
79. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors
associated with injection omission/non-adherence in the Global Atti
tudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes
Metab. In press 2012.
80. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin
81. DeFronzo RA, Rattner RE, Han J, Kim DD, Fineman MS, Baron AD.
Effects of exenatide (exendin-4) on glycemic control and weight over
and safety comparison of liraglutide, glimepiride, and placebo, all in
combination with metformin, in type 2 diabetes: the LEAD (liraglutide ef
O20 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor
sitagliptin added to ongoing metformin therapy in patients with type 2
diabetes inadequately controlled with metformin alone. Diabetes Care.
2006;29(12):2638–2643.
The efficacy and safety of saxagliptin when added to metformin therapy
in patients with inadequately controlled type 2 diabetes with metformin
